Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00483301 | A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma | completed | Phase 2 | 34 | Mt. Sinai Medical Center, MiamiOTHER | 1 | May 3, 2012 | clinicaltrials |
| NCT00616564 | Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma | completed | Phase 2 | 36 | Mt. Sinai Medical Center, MiamiOTHER | 1 | May 3, 2012 | clinicaltrials |
| NCT00436410 | Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | completed | Early Phase 1 | 108 | National Institutes of Health Clinical Center (CC)NIH | 1 | May 2, 2012 | clinicaltrials |
| NCT00369395 | A Study of Volociximab in Metastatic Melanoma | terminated | Phase 2 | 19 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT00750399 | Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma | completed | Phase 1 | 10 | The New York Eye Cancer CenterOTHER | 1 | Apr 26, 2012 | clinicaltrials |
| NCT00035165 | EPO906 Therapy in Patients With Advanced Melanoma | completed | Phase 2 | 51 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 25, 2012 | clinicaltrials |
| NCT01584115 | Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) | unknown | Phase 1 / Phase 2 | 15 | Instituto de Investigação em ImunologiaOTHER | 1 | Apr 25, 2012 | clinicaltrials |
| NCT01048554 | Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System(MEL0107) | completed | Phase 2 | 34 | Mt. Sinai Medical Center, MiamiOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT01052142 | Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma | completed | Phase 1 | 12 | Lipotek Pty LtdINDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00138229 | Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma | terminated | Phase 2 | 6 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 29, 2012 | clinicaltrials |
| NCT00287131 | Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients | unknown | Phase 2 | 70 | Sheba Medical CenterOTHER_GOV | 1 | Mar 29, 2012 | clinicaltrials |
| NCT00828126 | PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma | completed | — | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 28, 2012 | clinicaltrials |
| NCT00438984 | Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 11 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00019019 | Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas | completed | Phase 1 | 70 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00091104 | Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 136 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00316901 | Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | completed | Phase 2 | 70 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00111696 | Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma | completed | Phase 1 | 18 | MedImmune LLCINDUSTRY | 1 | Mar 14, 2012 | clinicaltrials |
| NCT00542893 | A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine | completed | Phase 1 | — | Genta IncorporatedINDUSTRY | 0 | Mar 13, 2012 | clinicaltrials |
| NCT01003626 | Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 22, 2012 | clinicaltrials |
| NCT00434057 | Evaluation of Pigmented Skin Lesions With MelaFind(R) System | completed | Phase 3 | 1,383 | MELA Sciences, Inc.INDUSTRY | 1 | Feb 14, 2012 | clinicaltrials |
| NCT01011153 | Survey Study - Sensitivity Comparison Between MelaFind and Physician Group | completed | — | 241 | MELA Sciences, Inc.INDUSTRY | 0 | Feb 14, 2012 | clinicaltrials |
| NCT00925314 | A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma | unknown | Phase 2 | 20 | Cosmo BioscienceINDUSTRY | 1 | Feb 13, 2012 | clinicaltrials |
| NCT01409187 | IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 26, 2012 | clinicaltrials |
| NCT00002860 | SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 77 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 13, 2012 | clinicaltrials |
| NCT01106235 | Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma | terminated | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 21, 2011 | clinicaltrials |
| NCT00002882 | Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma | completed | Phase 3 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 13, 2011 | clinicaltrials |
| NCT00006233 | Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00803374 | Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 21, 2011 | clinicaltrials |
| NCT00002763 | High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma | unknown | Phase 3 | 1,000 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 21 | Nov 16, 2011 | clinicaltrials |
| NCT00006385 | Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Nov 8, 2011 | clinicaltrials |
| NCT01092585 | Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH | unknown | Phase 2 | 27 | Genta IncorporatedINDUSTRY | 1 | Nov 8, 2011 | clinicaltrials |
| NCT00409383 | Abraxane and Temodar Plus Genasense in Advanced Melanoma | unknown | Phase 1 | 28 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
| NCT00518895 | Trial of Dacarbazine With or Without Genasense in Advanced Melanoma(AGENDA) | completed | Phase 3 | 300 | Genta IncorporatedINDUSTRY | 12 | Nov 7, 2011 | clinicaltrials |
| NCT00184288 | Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response. | withdrawn | — | 0 | Norwegian University of Science and TechnologyOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00060710 | CP-461 in the Treatment of Patients With Advanced Melanoma | terminated | Phase 2 | 35 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00451880 | Study of XL281 in Adults With Solid Tumors | completed | Phase 1 | 180 | ExelixisINDUSTRY | 1 | Oct 13, 2011 | clinicaltrials |
| NCT00747825 | Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma | terminated | Phase 1 | 12 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT01438658 | Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma(UM) | recruiting | — | 250 | Hadassah Medical OrganizationOTHER | 1 | Sep 28, 2011 | clinicaltrials |
| NCT00698100 | Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines | completed | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 16, 2011 | clinicaltrials |
| NCT00204581 | Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases | completed | Phase 2 | 51 | University Hospital TuebingenOTHER | 1 | Aug 19, 2011 | clinicaltrials |
| NCT00324272 | Post-Operative Drainage Following Lymph Node Dissection | completed | Phase 4 | 74 | Oxford University Hospitals NHS TrustOTHER | 0 | Aug 11, 2011 | clinicaltrials |
| NCT00003690 | Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 48 | Mayo ClinicOTHER | 1 | Aug 3, 2011 | clinicaltrials |
| NCT00399113 | Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma | completed | Phase 1 | 12 | Pain TherapeuticsINDUSTRY | 1 | Jul 14, 2011 | clinicaltrials |
| NCT00734188 | Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma | completed | Phase 1 | 21 | Pain TherapeuticsINDUSTRY | 1 | Jul 14, 2011 | clinicaltrials |
| NCT00094653 | MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma | completed | Phase 3 | 1,783 | Bristol-Myers SquibbINDUSTRY | 13 | Jul 11, 2011 | clinicaltrials |
| NCT00003646 | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 78 | VicalINDUSTRY | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00044356 | Phase II Trial of Allovectin-7® for Metastatic Melanoma | completed | Phase 2 | 133 | VicalINDUSTRY | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00580060 | Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity | completed | Early Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00658437 | CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy | completed | Phase 2 | 31 | Cytavis Biopharma GmbHINDUSTRY | 1 | Jun 8, 2011 | clinicaltrials |
| NCT00471133 | Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation | completed | Phase 1 | 24 | Ichor Medical Systems IncorporatedINDUSTRY | 1 | Jun 7, 2011 | clinicaltrials |
Data updated 23 days agoSource updated May 3, 2012source: clinicaltrials